<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1889-836X</journal-id>
<journal-title><![CDATA[Revista de Osteoporosis y Metabolismo Mineral]]></journal-title>
<abbrev-journal-title><![CDATA[Rev Osteoporos Metab Miner]]></abbrev-journal-title>
<issn>1889-836X</issn>
<publisher>
<publisher-name><![CDATA[Sociedad Española de Investigaciones Óseas y Metabolismo Mineral]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1889-836X2020000100003</article-id>
<article-id pub-id-type="doi">10.4321/s1889-836x2020000100003</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Diferencias en el metabolismo mineral óseo hiperparatiroidismo primario normocalcémico respecto al hiperparatiroidismo primario clásico]]></article-title>
<article-title xml:lang="en"><![CDATA[Differences in bone mineral metabolism normocalcemic primary hyperparathyroidism with respect to classical primary hyperparathyroidism]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ramos Sosa]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Gómez]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Hernández Hernández]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Déniz García]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Gómez de Tejada Romero]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="A a"/>
<xref ref-type="aff" rid="A02"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Sosa Henríquez]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="A a"/>
<xref ref-type="aff" rid="A03"/>
</contrib>
</contrib-group>
<aff id="A01">
<institution><![CDATA[,Universidad de Las Palmas de Gran Canaria Instituto Universitario de Investigaciones Biomédicas y Sanitarias Grupo de Investigación en Osteoporosis y Metabolismo Mineral]]></institution>
<addr-line><![CDATA[Las Palmas de Gran Canaria ]]></addr-line>
<country>España</country>
</aff>
<aff id="A02">
<institution><![CDATA[,Universidad de Sevilla Departamento de Medicina ]]></institution>
<addr-line><![CDATA[Sevilla ]]></addr-line>
<country>España</country>
</aff>
<aff id="A03">
<institution><![CDATA[,Hospital Universitario Insular Unidad Metabólica Ósea ]]></institution>
<addr-line><![CDATA[Las Palmas de Gran Canaria ]]></addr-line>
<country>España</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>03</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>03</month>
<year>2020</year>
</pub-date>
<volume>12</volume>
<numero>1</numero>
<fpage>14</fpage>
<lpage>19</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_arttext&amp;pid=S1889-836X2020000100003&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_abstract&amp;pid=S1889-836X2020000100003&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_pdf&amp;pid=S1889-836X2020000100003&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Objetivo: El hiperparatiroidismo primario normocalcémico es una variedad menos conocida del hiperparatiroidismo primario clásico. Presentamos en este estudio sus manifestaciones clínicas y los datos relacionados con el metabolismo mineral óseo, tanto desde el punto de vista analítico como densitométrico, comparando los mismos con un grupo de pacientes afectos de hiperparatiroidismo primario clásico, con hipercalcemia.  Material y métodos: Estudio de casos y controles donde consideramos caso a pacientes afectos de hiperparatiroidismo primario normocalcémico (n=25) y control (n=25) a pacientes con hiperpartiroidismo primario con hipercalcemia (hiperparatiroidismo primario clásico). Se les efectuó una evaluación clínica completa con recogida de datos clínicos y realizándose determinaciones analíticas en sangre y orina de 24h, así como la estimación de la densidad mineral ósea y el trabecular bone score por densitometría (absorciometría radiológica dual, DXA) y los parámetros ultrasonográficos en el calcáneo.  Resultados: En el estudio clínico, los pacientes afectos de hiperparatiroidismo primario clásico solo muestran una mayor prevalencia de urolitiasis (OR: 9,333; IC 95%: 1,50-82,7) en comparación con los pacientes que sufren un hiperparatiroidismo primario normocalcémico. En todos los demás parámetros clínicos, analíticos, densitométricos y ultrasonográficos, no se aprecian diferencias estadísticamente significativas entre ambos grupos.  Conclusiones: Con la excepción de los niveles séricos de calcio y la prevalencia de urolitiasis, el hiperparatiroidismo normocalcémico cursa de manera indistinguible del hiperparatiroidismo clásico.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Resumen  Objetive: Normocalcemic primary hyperparathyroidism is a less known variety of classical primary hyperparathyroidism. In this paper, we present its clinical expression and data related to bone mineral metabolism, both analytically and densitometrically, comparing them with a group of patients with classic primary hyperparathyroidism, with hypercalcemia.  Material and methods: Study of cases and controls where we consider case of patients with normocalcemic primary hyperparathyroidism (n=25) and control (n=25) of patients with primary hyperpartyroidism with hypercalcemia (classical primary hyperparathyroidism). A complete clinical assessment was carried out with clinical data collection and 24h blood and urine analytical determinations were performed, as well as estimating bone mineral density and trabecular bone score by densitometry (dual x-ray absorptiometry, DXA) and ultrasound parameters in the calcaneus.  Results: In this clinical study, patients with classic primary hyperparathyroidism only show a higher prevalence of urolithiasis (OR: 9.333; 95% CI: 1.50-82.7) compared to patients suffering from a normocalcemic primary hyperparathyroidism. In all other clinical, analytical, densitometric and ultrasonographic parameters, there are no statistically significant differences between the two groups.  Conclusions: Apart from serum calcium levels and the prevalence of urolithiasis, normocalcemic hyperparathyroidism is indistinguishable from classical hyperparathyroidism.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Hiperparatiroidismo]]></kwd>
<kwd lng="es"><![CDATA[primario]]></kwd>
<kwd lng="es"><![CDATA[normocalcémico]]></kwd>
<kwd lng="es"><![CDATA[densitometría]]></kwd>
<kwd lng="es"><![CDATA[cantidad]]></kwd>
<kwd lng="es"><![CDATA[calidad]]></kwd>
<kwd lng="es"><![CDATA[hueso]]></kwd>
<kwd lng="en"><![CDATA[Hyperparathyroidism]]></kwd>
<kwd lng="en"><![CDATA[primary]]></kwd>
<kwd lng="en"><![CDATA[normocalcemic]]></kwd>
<kwd lng="en"><![CDATA[densitometry]]></kwd>
<kwd lng="en"><![CDATA[quantity]]></kwd>
<kwd lng="en"><![CDATA[quality]]></kwd>
<kwd lng="en"><![CDATA[bone]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Yuan]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Primary hyperparathyroidism]]></article-title>
<source><![CDATA[Clin Case Reports]]></source>
<year>2019</year>
<volume>7</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>849-50</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sfeir]]></surname>
<given-names><![CDATA[JG]]></given-names>
</name>
<name>
<surname><![CDATA[Drake]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Normocalcemic primary hyperparathyroidism]]></article-title>
<source><![CDATA[Hyperparathyroidism: A Clinical Casebook]]></source>
<year>2016</year>
<page-range>157</page-range><publisher-name><![CDATA[Springer International Publishing]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cusano]]></surname>
<given-names><![CDATA[NE]]></given-names>
</name>
<name>
<surname><![CDATA[Maalouf]]></surname>
<given-names><![CDATA[NM]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[PY]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Cremers]]></surname>
<given-names><![CDATA[SC]]></given-names>
</name>
<name>
<surname><![CDATA[Haney]]></surname>
<given-names><![CDATA[EM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Normocalcemic hyperparathyroidism and hypoparathyroidism in two community-based nonreferral populations]]></article-title>
<source><![CDATA[J Clin Endocrinol Metab]]></source>
<year>2013</year>
<volume>98</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>2734-41</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cusano]]></surname>
<given-names><![CDATA[NE]]></given-names>
</name>
<name>
<surname><![CDATA[Cipriani]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Bilezikian]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Management of normocalcemic primary hyperparathyroidism]]></article-title>
<source><![CDATA[Best Pract Res Clin Endocrinol Metab]]></source>
<year>2018</year>
<volume>32</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>837-45</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Isakova]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Wolf]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[FGF23 or PTH: Which comes first in CKD]]></article-title>
<source><![CDATA[Kidney Int]]></source>
<year>2010</year>
<volume>78</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>947-9</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bilezikian]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Silverberg]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Normocalcemic primary hyperparathyroidism]]></article-title>
<source><![CDATA[Arq Bras Endocrinol Metabol]]></source>
<year>2010</year>
<volume>54</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>106-9</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Al-Azem]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Khan]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Primary Hyperparathyroidism]]></article-title>
<source><![CDATA[CAMJ]]></source>
<year>2011</year>
<volume>183</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>685-9</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bilezikian]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Khan]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
<name>
<surname><![CDATA[Potts]]></surname>
<given-names><![CDATA[JT]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Guidelines for the management of asymptomatic primary hyperparathyroidism: Summary statement from the third international workshop]]></article-title>
<source><![CDATA[J Clin Endocrinol Metab]]></source>
<year>2009</year>
<volume>94</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>335-9</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Marques]]></surname>
<given-names><![CDATA[TF]]></given-names>
</name>
<name>
<surname><![CDATA[Vasconcelos]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Diniz]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Rêgo]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Griz]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Bandeira]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Normocalcemic primary hyperparathyroidism in clinical practice: an indolent condition or a silent threat?]]></article-title>
<source><![CDATA[Arq Bras Endocrinol Metab]]></source>
<year>2011</year>
<volume>55</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>314-7</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Xue]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[Q]]></given-names>
</name>
<name>
<surname><![CDATA[Xue]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Yao]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Huang]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Is normocalcemic primary hyperparathyroidism harmful or harmless?]]></article-title>
<source><![CDATA[J Clin Endocrinol Metab]]></source>
<year>2015</year>
<volume>100</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>2420-4</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pawlowska]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Cusano]]></surname>
<given-names><![CDATA[NE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[An overview of normocalcemic primary hyperparathyroidism]]></article-title>
<source><![CDATA[Curr Opin Endocrinol Diabetes Obes]]></source>
<year>2015</year>
<volume>22</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>413-21</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bilezikian]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Potts]]></surname>
<given-names><![CDATA[JT]]></given-names>
</name>
<name>
<surname><![CDATA[El-Hajj Fuleihan]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Kleerekoper]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Neer]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Peacock]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Summary statement from a workshop on asymptomatic primary hyperparathyroidism: A perspective for the 21st century]]></article-title>
<source><![CDATA[J Clin Endocrinol Metab]]></source>
<year>2002</year>
<volume>87</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>5353-61</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Levey]]></surname>
<given-names><![CDATA[AS]]></given-names>
</name>
<name>
<surname><![CDATA[Coresh]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Greene]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Stevens]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Hendriksen]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate]]></article-title>
<source><![CDATA[Ann Intern Med]]></source>
<year>2006</year>
<volume>145</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>247-54</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Stevens]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
<name>
<surname><![CDATA[Coresh]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Greene]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Levey]]></surname>
<given-names><![CDATA[AS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Assessing kidney function - Measured and estimated glomerular filtration rate]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2006</year>
<volume>354</volume>
<numero>23</numero>
<issue>23</issue>
<page-range>2473-83</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rosenquist]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Fledelius]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Christgau]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Pedersen]]></surname>
<given-names><![CDATA[BJ]]></given-names>
</name>
<name>
<surname><![CDATA[Bonde]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Qvist]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Serum CrossLaps One Step ELISA. First application of monoclonal antibodies for measurement in serum of bone-related degradation products from C-terminal telopeptides of type I collagen]]></article-title>
<source><![CDATA[Clin Chem]]></source>
<year>1998</year>
<volume>44</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>2281-9</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Domínguez Cabrera]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Sosa-Henríquez]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Traba]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Alvarez Villafañe]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Piedra]]></surname>
<given-names><![CDATA[C De La]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Biochemical markers bone formation in the study of postmenopausal osteoporosis]]></article-title>
<source><![CDATA[Osteoporos Int]]></source>
<year>1998</year>
<volume>8</volume>
<page-range>147-51</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Piedra]]></surname>
<given-names><![CDATA[C De La]]></given-names>
</name>
<name>
<surname><![CDATA[Traba]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Domínguez Cabrera]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Sosa-Henríquez]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Biochemical markers of bone resorption in the study of postmenopausal osteoporosis]]></article-title>
<source><![CDATA[Clin Chim Acta]]></source>
<year>1997</year>
<volume>265</volume>
<page-range>225-34</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Garnero]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Vergnaud]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Hoyle]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Evaluation of a fully automated serum assay for total N-terminal propeptide of type I collagen in postmenopausal osteoporosis]]></article-title>
<source><![CDATA[Clin Chem]]></source>
<year>2008</year>
<volume>54</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>188-96</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sosa]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Saavedra]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Muñoz-Torres]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Alegre]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Gómez]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[González-Macías]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Quantitative ultrasound calcaneus measurements: Normative data and precision in the Spanish population]]></article-title>
<source><![CDATA[Osteoporos Int]]></source>
<year>2002</year>
<volume>13</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>487-92</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sosa]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Hernández]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Estévez]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Rodríguez]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Limiñana]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Saavedra]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The range of bone mineral density in healthy canarian women by dual X-ray absorptiometry radiography and quantitative computer tomography]]></article-title>
<source><![CDATA[J Clin Densitom]]></source>
<year>1998</year>
<volume>4</volume>
<page-range>385-93</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cano]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Pino del Montes]]></surname>
<given-names><![CDATA[J del]]></given-names>
</name>
<name>
<surname><![CDATA[Rio]]></surname>
<given-names><![CDATA[LM Del]]></given-names>
</name>
<name>
<surname><![CDATA[Di Gregorio]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[García-Vadillo]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Gómez]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Valores referencia TBS en población sana española de ambos sexos. Proyecto SEIOMM-TBS]]></article-title>
<source><![CDATA[Rev Osteoporos Metab Miner]]></source>
<year>2017</year>
<volume>9</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>5-7</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<collab>World Medical Association</collab>
<article-title xml:lang=""><![CDATA[World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>2013</year>
<volume>310</volume>
<numero>20</numero>
<issue>20</issue>
<page-range>2013-6</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pothuaud]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Barthe]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Krieg]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Mehsen]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Carceller]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Hans]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Evaluation of the Potential Use of Trabecular Bone Score to Complement Bone Mineral Density in the Diagnosis of Osteoporosis: A Preliminary Spine BMD-Matched, Case-Control Study]]></article-title>
<source><![CDATA[J Clin Densitom]]></source>
<year>2009</year>
<volume>12</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>170-6</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Silva]]></surname>
<given-names><![CDATA[BC]]></given-names>
</name>
<name>
<surname><![CDATA[Boutroy]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[McMahon]]></surname>
<given-names><![CDATA[DJ]]></given-names>
</name>
<name>
<surname><![CDATA[Zhou]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Trabecular bone score (TBS)-A novel method to evaluate bone microarchitectural texture in patients with primary hyperparathyroidism]]></article-title>
<source><![CDATA[J Clin Endocrinol Metab]]></source>
<year>2013</year>
<volume>98</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>1963-70</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Silva]]></surname>
<given-names><![CDATA[BC]]></given-names>
</name>
<name>
<surname><![CDATA[Leslie]]></surname>
<given-names><![CDATA[WD]]></given-names>
</name>
<name>
<surname><![CDATA[Resch]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Lamy]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Lesnyak]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Binkley]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Trabecular bone score: A noninvasive analytical method based upon the DXA image]]></article-title>
<source><![CDATA[J Bone Miner Res]]></source>
<year>2014</year>
<volume>29</volume>
<page-range>518-30</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Harvey]]></surname>
<given-names><![CDATA[NC]]></given-names>
</name>
<name>
<surname><![CDATA[Glüer]]></surname>
<given-names><![CDATA[CC]]></given-names>
</name>
<name>
<surname><![CDATA[Binkley]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[McCloskey]]></surname>
<given-names><![CDATA[EV]]></given-names>
</name>
<name>
<surname><![CDATA[Brandi]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
<name>
<surname><![CDATA[Cooper]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Trabecular bone score (TBS) as a new complementary approach for osteoporosis evaluation in clinical practice]]></article-title>
<source><![CDATA[J Clin Densitom]]></source>
<year>2013</year>
<volume>98</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>1963-70</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Leslie]]></surname>
<given-names><![CDATA[WD]]></given-names>
</name>
<name>
<surname><![CDATA[Krieg]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Hans]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical factors associated with trabecular bone score]]></article-title>
<source><![CDATA[J Clin Densitom]]></source>
<year>2013</year>
<volume>16</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>374-9</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Raum]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Grimal]]></surname>
<given-names><![CDATA[Q]]></given-names>
</name>
<name>
<surname><![CDATA[Varga]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Barkmann]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Glüer]]></surname>
<given-names><![CDATA[CC]]></given-names>
</name>
<name>
<surname><![CDATA[Laugier]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Ultrasound to assess bone quality]]></article-title>
<source><![CDATA[Curr Osteoporos Rep]]></source>
<year>2014</year>
<volume>12</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>154-62</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wallach]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Feinblatt]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
<name>
<surname><![CDATA[Carstens]]></surname>
<given-names><![CDATA[JH]]></given-names>
</name>
<name>
<surname><![CDATA[Avioli]]></surname>
<given-names><![CDATA[LV]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The bone "quality" problem]]></article-title>
<source><![CDATA[Calcif Tissue Int]]></source>
<year>1992</year>
<volume>51</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>169-72</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Amaral]]></surname>
<given-names><![CDATA[LM]]></given-names>
</name>
<name>
<surname><![CDATA[Queiroz]]></surname>
<given-names><![CDATA[DC]]></given-names>
</name>
<name>
<surname><![CDATA[Marques]]></surname>
<given-names><![CDATA[TF]]></given-names>
</name>
<name>
<surname><![CDATA[Mendes]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Bandeira]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Normocalcemic versus hypercalcemic primary hyperparathyroidism: More stone than bone?]]></article-title>
<source><![CDATA[J Osteoporos]]></source>
<year>2012</year>
<volume>2012</volume>
</nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Khan]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
<name>
<surname><![CDATA[Hanley]]></surname>
<given-names><![CDATA[DA]]></given-names>
</name>
<name>
<surname><![CDATA[Rizzoli]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Bollerslev]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Young]]></surname>
<given-names><![CDATA[JEM]]></given-names>
</name>
<name>
<surname><![CDATA[Rejnmark]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Primary hyperparathyroidism: review and recommendations on evaluation, diagnosis, and management. A Canadian and international consensus]]></article-title>
<source><![CDATA[Osteoporos Int]]></source>
<year>2017</year>
<volume>28</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1-19</page-range></nlm-citation>
</ref>
<ref id="B32">
<label>32</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Clarke]]></surname>
<given-names><![CDATA[BL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Asymptomatic Primary Hyperparathyroidism]]></article-title>
<source><![CDATA[Front Horm Res]]></source>
<year>2018</year>
<volume>51</volume>
<page-range>13-22</page-range></nlm-citation>
</ref>
<ref id="B33">
<label>33</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Costa-Guda]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Arnold]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hyperparathyroidism]]></article-title>
<source><![CDATA[Genet Bone Biol Skelet Dis]]></source>
<year>2017</year>
<volume>391</volume>
<page-range>599-615</page-range></nlm-citation>
</ref>
<ref id="B34">
<label>34</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Minisola]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Gianotti]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Bhadada]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Silverberg]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Classical complications of primary hyperparathyroidism]]></article-title>
<source><![CDATA[Best Pract Res Clin Endocrinol Metab]]></source>
<year>2018</year>
<volume>32</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>791-803</page-range></nlm-citation>
</ref>
<ref id="B35">
<label>35</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Clarke]]></surname>
<given-names><![CDATA[BL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Asymptomatic Primary Hyperparathyroidism]]></article-title>
<source><![CDATA[Front Horm Res]]></source>
<year>2018</year>
<volume>51</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>13-22</page-range></nlm-citation>
</ref>
<ref id="B36">
<label>36</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Silverberg]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
<name>
<surname><![CDATA[Bilezikian]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The diagnosis and management of asymptomatic primary hyperparathyroidism]]></article-title>
<source><![CDATA[Nat Clin Pract Endocrinol Metab]]></source>
<year>2006</year>
<volume>2</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>494-503</page-range></nlm-citation>
</ref>
<ref id="B37">
<label>37</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Glendenning]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Inderjeeth]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[Holick]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Measuring vitamin D]]></article-title>
<source><![CDATA[Clin Biochem]]></source>
<year>2012</year>
<volume>38</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>901-6</page-range></nlm-citation>
</ref>
<ref id="B38">
<label>38</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[McKenna]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Murray]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Vitamin D deficiency]]></article-title>
<source><![CDATA[Endocrinol Diabetes A Probl Approach]]></source>
<year>2014</year>
<numero>3</numero>
<issue>3</issue>
<page-range>293-304</page-range></nlm-citation>
</ref>
<ref id="B39">
<label>39</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dawson-Hughes]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Heaney]]></surname>
<given-names><![CDATA[RP]]></given-names>
</name>
<name>
<surname><![CDATA[Holick]]></surname>
<given-names><![CDATA[MF]]></given-names>
</name>
<name>
<surname><![CDATA[Lips]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Meunier]]></surname>
<given-names><![CDATA[PJ]]></given-names>
</name>
<name>
<surname><![CDATA[Vieth]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Estimates of optimal vitamin D status]]></article-title>
<source><![CDATA[Osteoporos Int]]></source>
<year>2005</year>
<volume>16</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>713-6</page-range></nlm-citation>
</ref>
<ref id="B40">
<label>40</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Silverberg]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
<name>
<surname><![CDATA[Lewiecki]]></surname>
<given-names><![CDATA[EM]]></given-names>
</name>
<name>
<surname><![CDATA[Mosekilde]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Peacock]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Rubin]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Presentation of asymptomatic primary hyperparathyroidism: Proceedings of the Third International Workshop]]></article-title>
<source><![CDATA[J Clin Endocrinol Metab]]></source>
<year>2009</year>
<volume>94</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>351-65</page-range></nlm-citation>
</ref>
<ref id="B41">
<label>41</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lips]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Vitamin D deficiency and secondary hyperparathyroidism in the elderly: Consequences for bone loss and fractures and therapeutic implications]]></article-title>
<source><![CDATA[Endocr Rev]]></source>
<year>2001</year>
<volume>22</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>477-501</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
